Abstract
Dipeptidyl peptidase-IV (DPP-IV) is well known to be an attractive therapeutic target to treat type II diabetes. The aim of this work is to determine the residues which make great contributions to inhibitor binding by comparing the interactions between different inhibitors and residues in DPP-IV. To achieve this, two DPP-IV/inhibitor complexes were studied by molecular dynamics simulations. Hydrogen bond and interaction energy analysis were then carried out. The results indicate that several residues could make great contributions to inhibitor binding. Medicinal chemists may have priority to choose these residues to form strong non-bonded interactions with designed compounds. It is hoped that this work could help medicinal chemists to design more potent DPP-IV inhibitors.
Keywords: Antidiabetic agent, DPP-IV, Inhibitor, Molecular dynamics simulation, Molecular Modeling, Type II diabetes.
Letters in Drug Design & Discovery
Title:Investigating the Contributions of Residues to Dipeptidyl Peptidase-IV Inhibitor Binding by Molecular Dynamics Simulation
Volume: 11 Issue: 7
Author(s): Mengyuan Liu, Xun Sun and Xian Zhao
Affiliation:
Keywords: Antidiabetic agent, DPP-IV, Inhibitor, Molecular dynamics simulation, Molecular Modeling, Type II diabetes.
Abstract: Dipeptidyl peptidase-IV (DPP-IV) is well known to be an attractive therapeutic target to treat type II diabetes. The aim of this work is to determine the residues which make great contributions to inhibitor binding by comparing the interactions between different inhibitors and residues in DPP-IV. To achieve this, two DPP-IV/inhibitor complexes were studied by molecular dynamics simulations. Hydrogen bond and interaction energy analysis were then carried out. The results indicate that several residues could make great contributions to inhibitor binding. Medicinal chemists may have priority to choose these residues to form strong non-bonded interactions with designed compounds. It is hoped that this work could help medicinal chemists to design more potent DPP-IV inhibitors.
Export Options
About this article
Cite this article as:
Liu Mengyuan, Sun Xun and Zhao Xian, Investigating the Contributions of Residues to Dipeptidyl Peptidase-IV Inhibitor Binding by Molecular Dynamics Simulation, Letters in Drug Design & Discovery 2014; 11 (7) . https://dx.doi.org/10.2174/1570180811666140226235522
DOI https://dx.doi.org/10.2174/1570180811666140226235522 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells for Hepatic Regeneration: The Role of Adipose Tissue Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Growth Retardation in Children with Celiac Disease
Current Pediatric Reviews Recombinant Hepatitis B Vaccination in Renal Failure Patients
Current Pharmaceutical Biotechnology The Role of the Heme Oxygenase System in the Metabolic Syndrome
Current Pharmaceutical Design Fast Food Versus Slow Food and Hypertension Control
Current Hypertension Reviews Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Human Wharton's Jelly Mesenchymal Stem Cells Maintain the Expression of Key Immunomodulatory Molecules When Subjected to Osteogenic, Adipogenic and Chondrogenic Differentiation In Vitro: New Perspectives for Cellular Therapy
Current Stem Cell Research & Therapy Irritable Bowel Syndrome: A Clinical Review
Current Rheumatology Reviews Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Research Progress on the Natural Product Aloperine and Its Derivatives
Mini-Reviews in Medicinal Chemistry Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Bilosomes: Superior Vesicular Carriers
Current Drug Therapy Virus-based Gene Transfer Approaches and Adipose Tissue Biology
Current Gene Therapy Editorial [Hot Topic: Endocrine Disruption and Reproduction (Guest Editor: Peter C.K. Leung)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Similar and Shared Nongenomic Mechanisms of Action of Estrogen and Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma
Endocrine, Metabolic & Immune Disorders - Drug Targets